Cargando…
The hypocretins and the reward function: what have we learned so far?
A general consensus acknowledges that drug consumption (including alcohol, tobacco, and illicit drugs) constitutes the leading cause of preventable death worldwide. But the global burden of drug abuse extends the mortality statistics. Indeed, the comorbid long-term debilitating effects of the diseas...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680710/ https://www.ncbi.nlm.nih.gov/pubmed/23781178 http://dx.doi.org/10.3389/fnbeh.2013.00059 |
_version_ | 1782273153079181312 |
---|---|
author | Boutrel, Benjamin Steiner, Nadia Halfon, Olivier |
author_facet | Boutrel, Benjamin Steiner, Nadia Halfon, Olivier |
author_sort | Boutrel, Benjamin |
collection | PubMed |
description | A general consensus acknowledges that drug consumption (including alcohol, tobacco, and illicit drugs) constitutes the leading cause of preventable death worldwide. But the global burden of drug abuse extends the mortality statistics. Indeed, the comorbid long-term debilitating effects of the disease also significantly deteriorate the quality of life of individuals suffering from addiction disorders. Despite the large body of evidence delineating the cellular and molecular adaptations induced by chronic drug consumption, the brain mechanisms responsible for drug craving and relapse remain insufficiently understood, and even the most recent developments in the field have not brought significant improvement in the management of drug dependence. Though, recent preclinical evidence suggests that disrupting the hypocretin (orexin) system may serve as an anticraving medication therapy. Here, we discuss how the hypocretins, which orchestrate normal wakefulness, metabolic health and the execution of goal-oriented behaviors, may be compromised and contribute to elicit compulsive drug seeking. We propose an overview on the most recent studies demonstrating an important role for the hypocretin neuropeptide system in the regulation of drug reward and the prevention of drug relapse, and we question the relevance of disrupting the hypocretin system to alleviate symptoms of drug addiction. |
format | Online Article Text |
id | pubmed-3680710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-36807102013-06-18 The hypocretins and the reward function: what have we learned so far? Boutrel, Benjamin Steiner, Nadia Halfon, Olivier Front Behav Neurosci Neuroscience A general consensus acknowledges that drug consumption (including alcohol, tobacco, and illicit drugs) constitutes the leading cause of preventable death worldwide. But the global burden of drug abuse extends the mortality statistics. Indeed, the comorbid long-term debilitating effects of the disease also significantly deteriorate the quality of life of individuals suffering from addiction disorders. Despite the large body of evidence delineating the cellular and molecular adaptations induced by chronic drug consumption, the brain mechanisms responsible for drug craving and relapse remain insufficiently understood, and even the most recent developments in the field have not brought significant improvement in the management of drug dependence. Though, recent preclinical evidence suggests that disrupting the hypocretin (orexin) system may serve as an anticraving medication therapy. Here, we discuss how the hypocretins, which orchestrate normal wakefulness, metabolic health and the execution of goal-oriented behaviors, may be compromised and contribute to elicit compulsive drug seeking. We propose an overview on the most recent studies demonstrating an important role for the hypocretin neuropeptide system in the regulation of drug reward and the prevention of drug relapse, and we question the relevance of disrupting the hypocretin system to alleviate symptoms of drug addiction. Frontiers Media S.A. 2013-06-13 /pmc/articles/PMC3680710/ /pubmed/23781178 http://dx.doi.org/10.3389/fnbeh.2013.00059 Text en Copyright © 2013 Boutrel, Steiner and Halfon. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. |
spellingShingle | Neuroscience Boutrel, Benjamin Steiner, Nadia Halfon, Olivier The hypocretins and the reward function: what have we learned so far? |
title | The hypocretins and the reward function: what have we learned so far? |
title_full | The hypocretins and the reward function: what have we learned so far? |
title_fullStr | The hypocretins and the reward function: what have we learned so far? |
title_full_unstemmed | The hypocretins and the reward function: what have we learned so far? |
title_short | The hypocretins and the reward function: what have we learned so far? |
title_sort | hypocretins and the reward function: what have we learned so far? |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680710/ https://www.ncbi.nlm.nih.gov/pubmed/23781178 http://dx.doi.org/10.3389/fnbeh.2013.00059 |
work_keys_str_mv | AT boutrelbenjamin thehypocretinsandtherewardfunctionwhathavewelearnedsofar AT steinernadia thehypocretinsandtherewardfunctionwhathavewelearnedsofar AT halfonolivier thehypocretinsandtherewardfunctionwhathavewelearnedsofar AT boutrelbenjamin hypocretinsandtherewardfunctionwhathavewelearnedsofar AT steinernadia hypocretinsandtherewardfunctionwhathavewelearnedsofar AT halfonolivier hypocretinsandtherewardfunctionwhathavewelearnedsofar |